论文部分内容阅读
目的观察中药分阶段结合化疗治疗晚期肺腺癌的临床疗效。方法采用前瞻、随机、对照的临床研究方法,将103例患者分为治疗组52例和对照组51例。对照组仅给予单纯化疗;治疗组在化疗期间服用抗瘤增效方,化疗结束后长期服用肺岩宁方。观察两组近期疗效、生存期、不良反应及治疗前后生活质量、主要临床症状、免疫功能、肿瘤标志物变化情况。结果治疗组有效率(CR+PR)为28.85%,稳定率(CR+PR+NC)为82.69%;中位生存期为14.47个月,1、2、3、5年生存率分别为55.77%、25.00%、13.46%、5.77%。对照组有效率为21.57%,稳定率为76.47%;中位生存期为10.97个月,1年、2年生存率分别为43.14%、7.84%,无3年、5年生存病例。治疗组在改善患者生活质量、神疲乏力、气短、腰膝酸软、头晕及免疫功能、肿瘤标志物等方面优于对照组(P<0.01);不良反应观察,治疗组出现白细胞减少症、恶心呕吐等消化道反应病例少于对照组(P<0.05)。结论中药分阶段结合化疗能够延长晚期肺腺癌的生存期,明显改善患者生存质量。
Objective To observe the clinical efficacy of traditional Chinese medicine combined with chemotherapy in the treatment of advanced lung adenocarcinoma. Methods Using prospective, randomized, controlled clinical research methods, 103 patients were divided into treatment group (52 cases) and control group (51 cases). The control group was given only chemotherapy alone; the treatment group took anti-tumor and potentiation during chemotherapy, and after a long period of chemotherapy, it was taken for a long time. The two groups were observed the short-term efficacy, survival, adverse reactions and quality of life before and after treatment, the main clinical symptoms, immune function, tumor markers changes. Results The effective rate (CR + PR) of the treatment group was 28.85%, the stability rate was (CR + PR + NC) 82.69%, the median survival time was 14.47 months, and the survival rates at 1, 2, 3 and 5 years were 55.77% , 25.00%, 13.46%, 5.77%. In the control group, the effective rate was 21.57% and the stability rate was 76.47%. The median survival time was 10.97 months. The 1-year and 2-year survival rates were 43.14% and 7.84% respectively. There were no 3-year and 5-year survival cases. The treatment group was better than the control group (P <0.01) in improving the quality of life of patients, Shenpi fatigue, shortness of breath, weakness of waist and knees, dizziness and immune function, tumor markers and other aspects; Adverse reactions observed, leukopenia, Vomiting and other gastrointestinal reactions less cases than the control group (P <0.05). Conclusion Traditional Chinese medicine combined with chemotherapy in stages can prolong the survival of advanced lung adenocarcinoma and improve the quality of life of patients.